GB-115
People mainly take GB-115 for anxiety. Based on 2 first-hand reports. Ranked #1632 of 2,750 overall.
14
User score
Mostly positive50% positive0% mixed0% negative50% unclear
Of reports that state an outcome, 100% are positive.
Clinical research
Research pending
High-risk compound. Peptides are not approved as supplements, carry serious and sometimes irreversible risks, are banned in competitive sport and may be restricted where you live. Nothing here is a recommendation to use it.
What GB-115 does, according to users
Of the people who reported each effect, the share who said it got better.
betterno changeworse
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
Research data for GB-115 is being compiled.
Dosage people report
As stated by users — not a recommendation. Follow the label or your doctor.
400 mcgas reported
two spraysas needed
Reported side effects
How often each side effect came up across all reports.
No side effects reported so far.
What users say
Verbatim quotes, shortened only — each links to the original discussion.
“GB115 is pro-cognitive but it probably doesn't belong under the "limitless" umbrella unless you have an anxiety disorder.”
“Two sprays. INSTANTLY killed my anxiety. Pretty insane.”
Other options for anxiety
Retatrutide
Peptide · 440 reports
40% report better anxiety
Mostly positiveBResearch: Moderate
Caffeine + L-Theanine
Supplement · 90 reports
100% report better anxiety
Mostly positive
Exercise
Lifestyle · 729 reports
95% report better anxiety
Mostly positive
Intermittent Fasting
Lifestyle · 255 reports
86% report better anxiety
Mostly positive
Magnesium Malate
Supplement · 138 reports
64% report better anxiety
Mostly positiveDResearch: None
Agmatine Sulfate
Supplement · 183 reports
95% report better anxiety
Mostly positiveCResearch: Limited
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 3, 2026. How we rate